Demonstration of consistency of results through replication is the ultimate goal of GROWTH Replicator: to test whether results obtained through the same protocols or procedures are commensurate. Transparency and reproducibility are key to the validity of reviews, and GROWTH Replicator will help users measure the transparency and reproducibility of their work.

The initial review to launch this site is one based on multiple myeloma produced by ICER, the Institute for Clinical and Economic Review. GROWTH Replicator makes this review and the research referenced within available for replication.


The Institute for Clinical and Economic Review (ICER) recently released two publications on the treatment of relapsing or refractory multiple myeloma. The draft report, Options for Relapsed or Refractory Multiple Myeloma: Effectiveness and Value, was released on April 7, 2016, and the final evidence report, Treatment Options for Relapsed or Refractory Multiple Myeloma: Effectiveness, Value, and Value-Based Price Benchmarks, was released on May 5, 2016. The purpose of this commentary is to provide transparency for the scientific community at large, and to give insights into ICER analysis’ data integrity and validity of their conclusions. The authors of this commentary intend this document to undergo continuous revisions to accommodate ongoing assessments made by DRE and the public audience. We have divided our commentary on the data integrity and analytical methods of ICER’s analysis into three topics: Technology, Transparency, and Methodology. In each of these topics we have identified specific concerns, and, in turn, attempted to address some of these issues through the GROWTH Replicator initiative.

Husain F, et al.

Don't see the Replication Report you're looking for?...

Suggest a specific review to replicate.